The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients.
about
Safe handling of oral antineoplastic medications: focus on targeted therapeutics in the home settingProtein Kinase CK2: A Targetable BCR-ABL Partner in Philadelphia Positive LeukemiasPlatelet adhesion to podoplanin under flow is mediated by the receptor CLEC-2 and stabilised by Src/Syk-dependent platelet signalling.Targeted therapy with MXD3 siRNA, anti-CD22 antibody and nanoparticles for precursor B-cell acute lymphoblastic leukaemia.Spred2 modulates the erythroid differentiation induced by imatinib in chronic myeloid leukemia cellsSRC drives growth of antiestrogen resistant breast cancer cell lines and is a marker for reduced benefit of tamoxifen treatmentImproved angiostatic activity of dasatinib by modulation with hydrophobic chainsNovel synthesizing method of pH-dependent doxorubicin-loaded anti-CD22-labelled drug delivery nanosystemDasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034.Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial.Jellyfish extract induces apoptotic cell death through the p38 pathway and cell cycle arrest in chronic myelogenous leukemia K562 cells.Causes of resistance and treatment choices of second- and third-line treatment in chronic myelogenous leukemia patients.2-Aminoxazole and 2-Aminothiazole Dasatinib Derivatives as Potent Inhibitors of Chronic Myeloid Leukemia K562 Cells.Upfront treatment with the first and second-generation tyrosine kinase inhibitors in Ph-positive acute lymphoblastic leukemia.Differential Expression of Circadian Genes in Leukemia and a Possible Role for Sirt1 in Restoring the Circadian Clock in Chronic Myeloid Leukemia.Clinical Pharmacology Tools and Evaluations to Facilitate Comprehensive Dose Finding in Oncology: A Continuous Risk-Benefit Approach.The calcineurin protein phosphatase is dispensable for BCR-ABL-induced B-ALL maintenance, propagation and response to dasatinib.Src inhibitors modulate frataxin protein levels.[Chronic myelogenous leukemia].The tyrosine kinase inhibitor dasatinib effectively blocks PDGF-induced orbital fibroblast activation.
P2860
Q23923997-4BBF606C-C5B8-4BC1-9555-4757E1329D3FQ26769590-FF2298F5-3B4E-4608-8509-CA15C628F08EQ27342857-5939321E-1846-459E-B0F8-24E47B8C5F86Q34416178-E38A40FF-BCB8-4A20-8958-79026F74F0F4Q35092057-410F694E-F127-4B11-90CD-1C6B23ADFCDBQ35113027-CA338756-B5A0-434E-89C0-4F82C816A5FCQ35178869-F816794F-3AD4-402B-B33C-F069DA8E6576Q36052352-035AAAD0-9B9E-4C16-9396-3629BC7DDB77Q37391801-0763B36A-9795-4DA8-A0E1-887FF781944AQ37427140-F4A7E722-EE2A-4FC1-84CA-EF6364BF5339Q37597446-57B1B46C-4CBF-43AE-B88D-7847A8E14ACEQ38392673-D36FDD8B-7E09-4338-A692-1380BA2F02E3Q38770334-4FE00026-148D-4268-A537-CBA971D6511FQ47104794-ED4A458B-BF18-4F0A-820C-7CBA04CE0B1EQ47159458-F15386D8-6D95-40C3-9BA3-9DD6C1B5627AQ47969034-4BF42219-7CC3-4ADF-A16F-5FAED0D1AA1EQ51439967-9182FF2F-91A4-4FAF-BBE6-5B2553D57E52Q53516540-60F42AC1-9A5B-4E90-BC3A-035714E7BF03Q54167458-6A8F0F6E-09C0-4726-89B7-3076B258D86BQ54349169-51BE1732-91EE-4653-AB83-A72698109435
P2860
The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The development of dasatinib a ...... n in newly diagnosed patients.
@en
type
label
The development of dasatinib a ...... n in newly diagnosed patients.
@en
prefLabel
The development of dasatinib a ...... n in newly diagnosed patients.
@en
P2860
P921
P1476
The development of dasatinib a ...... n in newly diagnosed patients.
@en
P2860
P2888
P304
P356
10.1007/S00432-013-1488-Z
P577
2013-08-13T00:00:00Z
2013-12-01T00:00:00Z